Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.29 and traded as low as $0.25. Northwest Biotherapeutics shares last traded at $0.25, with a volume of 5,114,851 shares.
Northwest Biotherapeutics Trading Down 0.3 %
The stock has a market capitalization of $342.91 million, a price-to-earnings ratio of -3.14 and a beta of -0.52. The stock has a 50-day simple moving average of $0.27 and a 200 day simple moving average of $0.29.
About Northwest Biotherapeutics
(
Get Free Report)
Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
Further Reading
Before you consider Northwest Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Northwest Biotherapeutics wasn't on the list.
While Northwest Biotherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
